-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis Drug Details Allergen...
-
Product Insights
House Dust Mite Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The House Dust Mite Allergy - Drugs In Development research report provides a comprehensive overview on the therapeutics under development for House Dust Mite Allergy, complete...